Benzinga | Nov 16, 2021 09:47AM EST

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and raises the price target from $12 to $20.